Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347773 (US9790220, Example 6) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347772 (US9790220, Example 5) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347777 (US9790220, Example 10) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 21 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347788 (US9790220, Example 21) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 24 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347786 (US9790220, Example 19) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 33 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347775 (US9790220, Example 8) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 34 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347785 (US9790220, Example 18) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 41 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347779 (US9790220, Example 12) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 42 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347769 (US9790220, Example 1) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 43 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347780 (US9790220, Example 13) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 69 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347793 (US9790220, Example 26 | US9790220, Example 27) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 71 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347776 (US9790220, Example 9) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 84 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347791 (US9790220, Example 24) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 86 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347787 (US9790220, Example 20) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347770 (US9790220, Example 2) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 128 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347782 (US9790220, Example 15) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 150 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347781 (US9790220, Example 14) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 170 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347771 (US9790220, Example 3) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 170 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347784 (US9790220, Example 17) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 210 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347790 (US9790220, Example 23) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 290 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347789 (US9790220, Example 22) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 300 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347778 (US9790220, Example 11) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 330 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347774 (US9790220, Example 7) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 540 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347783 (US9790220, Example 16) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 630 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347792 (US9790220, Example 25) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 660 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin/Hypocretin receptor type 1 (Homo sapiens (Human)) | BDBM347793 (US9790220, Example 26 | US9790220, Example 27) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 910 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347772 (US9790220, Example 5) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347775 (US9790220, Example 8) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.30E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347786 (US9790220, Example 19) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347793 (US9790220, Example 26 | US9790220, Example 27) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347785 (US9790220, Example 18) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347784 (US9790220, Example 17) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347792 (US9790220, Example 25) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347789 (US9790220, Example 22) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347782 (US9790220, Example 15) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347776 (US9790220, Example 9) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347777 (US9790220, Example 10) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347778 (US9790220, Example 11) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347781 (US9790220, Example 14) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347774 (US9790220, Example 7) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347791 (US9790220, Example 24) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347787 (US9790220, Example 20) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347769 (US9790220, Example 1) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347780 (US9790220, Example 13) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347773 (US9790220, Example 6) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347779 (US9790220, Example 12) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347771 (US9790220, Example 3) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347790 (US9790220, Example 23) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Orexin receptor type 2 (Homo sapiens (Human)) | BDBM347788 (US9790220, Example 21) | PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in... | US Patent US9790220 (2017) BindingDB Entry DOI: 10.7270/Q2FF3VHB | |||||||||||
More data for this Ligand-Target Pair |